CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Bristol Myers to merge scientific, clinical teams under new R&D structure

By Reuters News

Nov 12 (Reuters) - Bristol Myers Squibb BMY.N said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.

Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.

  • "Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," said CEO Christopher Boerner

  • Analysts are closely watching Bristol's drug development pipeline for clues on growth

  • "Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution," Boerner said

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk